Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Bone Marrow Transplant. 2023 Mar;58(3):273-281. doi: 10.1038/s41409-022-01883-4. Epub 2022 Dec 1.
Graft failure (GF) remains a serious issue of hematopoietic stem cell transplantation (HSCT) in inborn errors of immunity (IEI). Second HSCT is the only salvage therapy for GF. There are no uniform strategies for the second HSCTs and limited data are available on the second HSCT outcomes. 48 patients with various IEI received second allogeneic HSCT from 2013 to 2020. Different conditioning regimens were used, divided into two main groups: containing myeloablative doses of busulfan/treosulfan (n = 19) and lymphoid irradiation 2-6 Gy (n = 22). Irradiation-containing conditioning was predominantly used in suspected immune-mediated rejection of the first graft. Matched unrelated donor was used in 28 patients, mismatched related in 18, and matched related in 1. 35 patients received TCRαβ/CD19 graft depletion. The median follow-up time was 2.4 years post-HSCT. One patient died at conditioning. The OS was 0.63 (95% CI: 0.41-0.85) after busulfan/treosulfan and 0.68 (95% CI: 0.48-0.88) after irradiation-based conditioning, p = 0.66. Active infection at HSCT significantly influenced OS: 0.43 (95% CI: 0.17-0.69) versus 0.73 (95% CI: 0.58-0.88) without infection, p = 0.004. The cumulative incidence of GF was 0.15 (95% CI: 0.08-0.29). To conclude, an individualized approach is required for the second HSCT in IEI. Low-dose lymphoid irradiation in suspected immune-mediated GF may be a feasible option.
移植物失败(GF)仍然是遗传性免疫缺陷(IEI)患者造血干细胞移植(HSCT)的严重问题。第二 HSCT 是 GF 的唯一挽救疗法。第二 HSCT 没有统一的策略,并且关于第二 HSCT 结果的数据有限。2013 年至 2020 年,48 例不同 IEI 患者接受了第二异基因 HSCT。使用了不同的预处理方案,分为两组:含大剂量白消安/替莫唑胺(n=19)和 2-6Gy 淋巴细胞照射(n=22)。照射预处理主要用于怀疑首次移植物免疫介导排斥。28 例患者使用匹配的无关供体,18 例使用不匹配的亲缘供体,1 例使用匹配的亲缘供体。35 例患者接受 TCRαβ/CD19 移植物耗竭。HSCT 后中位随访时间为 2.4 年。1 例患者在预处理时死亡。白消安/替莫唑胺预处理后的 OS 为 0.63(95%CI:0.41-0.85),照射预处理后的 OS 为 0.68(95%CI:0.48-0.88),p=0.66。HSCT 时活动性感染显著影响 OS:0.43(95%CI:0.17-0.69)与无感染时 0.73(95%CI:0.58-0.88),p=0.004。GF 的累积发生率为 0.15(95%CI:0.08-0.29)。总之,IEI 患者的第二 HSCT 需要个体化治疗。疑似免疫介导的 GF 中低剂量淋巴细胞照射可能是一种可行的选择。